Literature DB >> 29550198

Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.

Wan Song1, Seok Hwan Bang2, Hwang Gyun Jeon2, Byong Chang Jeong2, Seong Il Seo2, Seong Soo Jeon2, Han Yong Choi3, Chan Kyo Kim4, Hyun Moo Lee5.   

Abstract

INTRODUCTION: The objective of this study was to investigate the effect of Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) on prediction of postoperative Gleason score (GS) upgrading for patients with biopsy GS 6 prostate cancer. PATIENTS AND METHODS: We retrospectively reviewed 443 patients who underwent magnetic resonance imaging (MRI) and radical prostatectomy for biopsy-proven GS 6 prostate cancer between January 2011 and December 2013. Preoperative clinical variables and pathologic GS were examined, and all MRI findings were assessed with PI-RADSv2. Receiver operating characteristic curves were used to compare predictive accuracies of multivariate logistic regression models with or without PI-RADSv2.
RESULTS: Of the total 443 patients, 297 (67.0%) experienced GS upgrading postoperatively. PI-RADSv2 scores 1 to 3 and 4 to 5 were identified in 157 (25.4%) and 286 (64.6%) patients, respectively, and the rate of GS upgrading was 54.1% and 74.1%, respectively (P < .001). In multivariate analysis, prostate-specific antigen density > 0.16 ng/mL2, number of positive cores ≥ 2, maximum percentage of cancer per core > 20, and PI-RADSv2 score 4 to 5 were independent predictors influencing GS upgrading (each P < .05). When predictive accuracies of multivariate models with or without PI-RADSv2 were compared, the model including PI-RADSv2 was shown to have significantly higher accuracy (area under the curve, 0.729 vs. 0.703; P = .041).
CONCLUSION: Use of PI-RADSv2 is an independent predictor of postoperative GS upgrading and increases the predictive accuracy of GS upgrading. PI-RADSv2 might be used as a preoperative imaging tool to determine risk classification and to help counsel patients with regard to treatment decision and prognosis of disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; PI-RADSv2; Prostate cancer; Radical prostatectomy; Upgrading

Mesh:

Substances:

Year:  2018        PMID: 29550198     DOI: 10.1016/j.clgc.2018.02.015

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  9 in total

1.  Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer.

Authors:  Young Hyo Choi; Ji Woong Yu; Min Yong Kang; Hyun Hwan Sung; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hwang Gyun Jeon
Journal:  World J Urol       Date:  2019-01-02       Impact factor: 4.226

2.  Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?

Authors:  Duc Minh Pham; Jung Kwon Kim; Sangchul Lee; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Investig Clin Urol       Date:  2020-05-25

3.  The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy.

Authors:  Wan Song; Minyong Kang; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hwang Gyun Jeon
Journal:  Investig Clin Urol       Date:  2019-09-11

4.  Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.

Authors:  Xiaochuan Wang; Yu Zhang; Fengbo Zhang; Zhengguo Ji; Peiqian Yang; Ye Tian
Journal:  BMC Urol       Date:  2021-01-06       Impact factor: 2.264

5.  Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.

Authors:  Antonio Benito Porcaro; Sebastian Gallina; Alberto Bianchi; Clara Cerrato; Alessandro Tafuri; Riccardo Rizzetto; Nelia Amigoni; Rossella Orlando; Emanuele Serafin; Alessandra Gozzo; Filippo Migliorini; Stefano Zecchini Antoniolli; Vincenzo Lacola; Vincenzo De Marco; Matteo Brunelli; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-10-22       Impact factor: 2.370

6.  CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer.

Authors:  Xiao-Ping Qin; Qi-Ji Lu; Cheng-Huizi Yang; Jue Wang; Jian-Fan Chen; Kan Liu; Xin Chen; Jing Zhou; Yu-Hang Pan; Yong-Hong Li; Shan-Cheng Ren; Jiu-Min Liu; Wei-Peng Liu; Hui-Jun Qian; Xian-Lin Yi; Cai-Yong Lai; Li-Jun Qu; Xin Gao; Yu-Sheng Xu; Zheng Chen; Yu-Min Zhuo
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

7.  Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging.

Authors:  Ola Christiansen; Ola Bratt; Øyvind Kirkevold; Jūratė Šaltytė Benth; Pathmakulendran Manoharan; Anders Selnes; Erik Skaaheim Haug; Marit Slaaen
Journal:  Cent European J Urol       Date:  2022-12-31

8.  Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.

Authors:  Xing Li; Zhi-Xian Wang; Yun-Peng Zhu; Jing Wang; Yi-Sheng Yin; Xiao-Yong Zeng
Journal:  Asian J Androl       Date:  2022 Sep-Oct       Impact factor: 3.054

9.  Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort.

Authors:  Baoling Zhang; Shangrong Wu; Yang Zhang; Mingyu Guo; Ranlu Liu
Journal:  Cancer Med       Date:  2021-09-16       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.